211 related articles for article (PubMed ID: 31404565)
1. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats.
Takakuwa M; Watanabe Y; Saijo T; Murata M; Anabuki J; Tezuka T; Sato S; Kojima K; Hashimoto K
Pharmacol Biochem Behav; 2020 Sep; 196():172972. PubMed ID: 32562717
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.
Suzuki K; Harada A; Suzuki H; Capuani C; Ugolini A; Corsi M; Kimura H
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417763
[TBL] [Abstract][Full Text] [Related]
4. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms.
Suzuki K; Harada A; Suzuki H; Miyamoto M; Kimura H
Neuropsychopharmacology; 2016 Aug; 41(9):2252-62. PubMed ID: 26849714
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.
Suzuki K; Harada A; Shiraishi E; Kimura H
J Pharmacol Exp Ther; 2015 Mar; 352(3):471-9. PubMed ID: 25525190
[TBL] [Abstract][Full Text] [Related]
7. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
Redrobe JP; Rasmussen LK; Christoffersen CT; Bundgaard C; Jørgensen M
Eur J Pharmacol; 2015 Aug; 761():79-85. PubMed ID: 25941078
[TBL] [Abstract][Full Text] [Related]
11. Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.
Harada A; Kaushal N; Suzuki K; Nakatani A; Bobkov K; Vekich JA; Doyle JP; Kimura H
Int J Neuropsychopharmacol; 2020 Feb; 23(2):96-107. PubMed ID: 31689714
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy.
Li YW; Seager MA; Wojcik T; Heman K; Molski TF; Fernandes A; Langdon S; Pendri A; Gerritz S; Tian Y; Hong Y; Gallagher L; Merritt JR; Zhang C; Westphal R; Zaczek R; Macor JE; Bronson JJ; Lodge NJ
Neuropharmacology; 2016 Mar; 102():121-35. PubMed ID: 26522433
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition.
Jones PG; Hewitt MC; Campbell JE; Quinton MS; Engel S; Lew R; Campbell U; Burdi DF
Pharmacol Biochem Behav; 2015 Aug; 135():46-52. PubMed ID: 25989044
[TBL] [Abstract][Full Text] [Related]
15. Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats.
Arakawa K; Maehara S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):190-195. PubMed ID: 32351052
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
18. The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.
Gentzel RC; Toolan D; Roberts R; Koser AJ; Kandebo M; Hershey J; Renger JJ; Uslaner J; Smith SM
Neuropharmacology; 2015 Dec; 99():256-63. PubMed ID: 26044638
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.
Weber M; Breier M; Ko D; Thangaraj N; Marzan DE; Swerdlow NR
Psychopharmacology (Berl); 2009 May; 203(4):723-35. PubMed ID: 19066855
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
